An Act amending the act of April 14, 1972 (P.L.233, No.64), known as The Controlled Substance, Drug, Device and Cosmetic Act, further providing for authority to control.

This bill requires Pennsylvania to align its scheduling of synthetic psilocybin with federal changes. Specifically, it mandates that after the U.S. Food and Drug Administration approves a federal scheduling change for synthetic psilocybin, the Pennsylvania Secretary of Health must schedule it within five business days and the change takes effect 30 days after publication in the Pennsylvania Bulletin. The law directly affects state health authorities and regulatory processes, ensuring Pennsylvania’s rules mirror federal actions without creating new medical uses or penalties. It does not alter current state restrictions but establishes a procedural mechanism for future alignment.